Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
about
The in vitro and vivo effects of nuclear and cytosolic parafibromin expression on the aggressive phenotypes of colorectal cancer cells: a search of potential gene therapy target.The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapyOrgan-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes.Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Alternative Chk1-independent S/M checkpoint in somatic cells that prevents premature mitotic entry.Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Transcriptome profiling identifies a recurrent CRYL1-IFT88 chimeric transcript in hepatocellular carcinoma.TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapyExpression, prognosis and functional role of Thsd7a in esophageal squamous cell carcinoma of Kazakh patients, Xinjiang.G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells.Danshen extract circumvents drug resistance and represses cell growth in human oral cancer cells.The therapeutic potential of cell cycle targeting in multiple myeloma.Moving synergistically acting drug combinations to the clinic by comparing sequential versus simultaneous drug administrations.Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.Epigenetic changes in the early stage of silica-induced cell transformation.TFPI2AS1, a novel lncRNA that inhibits cell proliferation and migration in lung cancer.Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of glioma cells by inactivating Wnt/β-catenin signaling.Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Evidence that PP2A activity is dispensable for spindle assembly checkpoint-dependent control of Cdk1.Cell-Cycle Therapeutics Come of Age.Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes
P2860
Q33618790-6580EA4A-49FE-49E7-8C6C-87588A551E49Q33739235-B7F67FBE-E8E8-452A-8AB6-B4D6B1926228Q36266131-690C1E78-B543-4A7B-AD8C-5812274CD52CQ36348567-FD8268B3-6517-4279-B8DC-1CE096BE68B7Q37709125-074D74D4-04E4-4EBB-A579-53447F1C0D7AQ38677841-3E4F1FD2-F158-4F60-9761-9A73382ECCCDQ38871888-B36F4495-0C46-4B7C-B0B1-F2535714CD1DQ39139241-B22D8799-C449-4D1B-9503-E1770DD2BF4DQ39233197-2D3C54A2-F6C7-4125-8212-9E3E5AC5B2D4Q41093037-36829E38-8AFC-4B74-B33E-865826AC7A98Q41431230-E04926A6-9399-49B4-8FAE-426E173B3D35Q41694312-99D80DA1-5B14-4FC9-BCCE-DB0A085635ACQ47133044-2EFAE966-5373-49E3-9A39-2982B1AF55FDQ47144489-54AB470E-031B-4AD9-B6FF-6A856BF473CCQ47203904-D2889840-9079-43AC-942A-050BCEB0B9E3Q47292160-A23F9758-B674-49E5-BF16-2BB2B2841059Q47602380-95A9EB66-535F-40D8-B6D1-9F0CB40E0DC0Q47730306-2219FCA1-AA7C-49EE-8FBD-3E4B230F7D8CQ47766662-14A2AFD7-AD2E-477A-97C0-8FA2DDA9E4C4Q48151514-8749524C-CE43-4521-8FC4-A0054E46E16AQ48227776-D7F910D6-54A7-44CA-8D76-EF67B47F2A4EQ49887888-D36F2A66-04D1-46F1-A53A-4E5F8B4E264DQ50332985-EB1528FF-86B0-40B4-BDD9-0D7A5C37F68EQ50959563-1C24612F-42D7-4074-8CD7-9866DCB6D702Q52726503-119A3027-324E-4CF5-A979-320D52458263Q57263190-E52C01A1-33B6-4593-87AE-0E9610673A65
P2860
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@ast
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@en
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@nl
type
label
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@ast
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@en
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@nl
prefLabel
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@ast
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@en
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@nl
P2860
P3181
P1476
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
@en
P2093
Domenico Grieco
Rosa Della Monica
P2860
P2888
P3181
P356
10.1186/S13046-016-0433-9
P407
P577
2016-09-27T00:00:00Z
P6179
1031184944